Cannabidiol

Portugal medicinal cannabis exports reached 66,305 kg in the first half of 2026, according to INFARMED, already 83% of the 79,883 kg shipped across all of 2025. The country’s medicines regulator published the figures in its mid-year report on the sector, which also shows cultivation and manufacturing licences easing back after several years of rapid expansion. Portugal began regulating medicinal cannabis in 2018, when the Assembly of the Republic approved a law covering marketing authorisations, prescribing and pharmacy dispensing. A […]

Is Portugal's cannabis market hitting the brakes? 📉🇵🇹 Recent cuts in licensing have visibly contracted the sector — reducing new entrants, cooling investment, and creating supply and patient-access pressures while forcing companies to reassess growth strategies. The article explains the regulatory shifts, market impacts, and what policymakers and businesses can do next. Read the full analysis to understand the implications and next steps for stakeholders. #SyenzaNews #regulatoryaffairs #pharmaceuticals #MarketAccess #governance

Cannabidiol has been licensed as an add-on treatment for seizures caused by tuberous sclerosis complex for patients aged 2 years and over. Clinical trial evidence shows that it reduces seizure frequency and increases seizure-free days compared to a placebo. While the cost-effectiveness estimates are uncertain, the benefits of reducing the severity of seizures and lowering the risk of sudden unexpected death in epilepsy make it an appropriate use of NHS resources. Therefore, it is recommended as a treatment option by […]